Showing 17,921 - 17,940 results of 105,667 for search '(( 5 ((ng decrease) OR (a decrease)) ) OR ( 50 ((mean decrease) OR (we decrease)) ))', query time: 1.15s Refine Results
  1. 17921

    DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  2. 17922

    DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  3. 17923

    DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  4. 17924

    DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  5. 17925

    DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

    Published 2021
    “…</p><p>Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. …”
  6. 17926
  7. 17927

    EGFR Signaling Regulates Maspin/SerpinB5 Phosphorylation and Nuclear Localization in Mammary Epithelial Cells by Mariana Tamazato Longhi (2889737)

    Published 2016
    “…<div><p>Maspin (SerpinB5) is a non-inhibitory serpin (<u>ser</u>ine <u>p</u>rotease <u>in</u>hibitor) with very diverse biological activities including regulation of cell adhesion, migration, death, control of gene expression and oxidative stress response. …”
  8. 17928

    Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea by Supattra Boonruang (4358479)

    Published 2017
    “…In this study, activity-guided isolation identified four flavonoids <b>1-4</b> (apigenin, luteolin, chrysoeriol, quercetin) from <i>Vernonia cinerea</i> and <i>Pluchea indica, </i>four hirsutinolide-type sesquiterpene lactones <b>5-8</b> from <i>V. cinerea</i>, and acetylenic thiophenes <b>9-11</b> from <i>P. indica</i> that inhibited CYP2A6- and CYP2A13-mediated coumarin 7-hydroxylation. …”
  9. 17929

    Coupled Human-Environment Dynamics of Forest Pest Spread and Control in a Multi-Patch, Stochastic Setting by Qasim Ali (802840)

    Published 2015
    “…The population of trees is distributed across 10 patches (parks) comprising a “low volume” partition of 5 patches that experience a low volume of park visitors, and a “high volume” partition of 5 patches experiencing a high visitor volume. …”
  10. 17930
  11. 17931
  12. 17932
  13. 17933
  14. 17934
  15. 17935

    Development of Nitric Oxide Releasing Oxoisoaporphines with Antidepressant Activities by Simultaneously Regulating MAO‑A and SERT by Peisen Zhong (13883434)

    Published 2024
    “…The occurrence of depression is closely related to the decrease in serotonin (5-HT) levels in the synaptic cleft. …”
  16. 17936
  17. 17937
  18. 17938
  19. 17939
  20. 17940

    Triboelectric Nanogenerators of the Li Salt of Adipic Acid-Incorporated Poly(vinyl alcohol) Composites Toward Biomechanical Motion Energy Harvesting and in Sports Application by Prasanjit K. Dey (19946302)

    Published 2024
    “…The open-circuit voltage in the PVA/Li-AA composite-based TENG of 15 wt % Li-AA registered ∼90 V and a short-circuit current of ∼45 μA. Moreover, the device showed a maximum power density of ∼2.75 W/m<sup>2</sup> at 2 MΩ resistance. …”